Amsterdam, 18 - 19 March 2020

Schedule

Create your personal agenda –check the favourite icon

Mar 1808:55
Conference pass

Chair’s opening remarks

Keynotes
Ryan Saadi, Vice President, Global Market Access, CSL Behring
Mar 1809:00
Conference pass

Innovation in industry and practical considerations for biotechs

Keynotes
Erik Van Den Berg, Chief Executive Officer, A.M. Pharma
Mar 1809:20
Conference pass

Trends in modelling approaches for successful reimbursement of ATMPs

Keynotes
Ion Agirrezabal, Senior Consultant, Covance Market Access And Phase Iv Solutions, Covance Market Access
Mar 1809:40
Conference pass

Unleash the Algorithms: Critical Success Factors to Reinvent Our Role in Delivering Patient Value

Keynotes
Bharat Tewarie, Executive Vice President And Chief Marketing Officer, UCB
Mar 1811:20
Conference pass

Virtual Research: What it Is & What it’s Doing in the Real-World Setting

Keynotes
Mar 1811:40
Conference pass

Orphan Drugs, Gene Therapies, Post-Marketing-Data: Latest developments in German legal framework for drug assessment and reimbursement

Keynotes
Thomas Mueller, Head Of Directorate General 1 "Drugs, Medical Devices, Biotechnology", Federal Ministry of Health Germany
Mar 1812:00
Conference pass

Roundtables

Keynotes
Roundtable 10: Accelerating access to treatments for rare diseases
Kate Adcock, Director Of Research And Innovation, The Muscular Dystrophy U.K.
Roundtable 11: Does pricing innovative drugs fairly improve your bottomline?
Michael Schroter, Partner, Viopas Partners
Roundtable 12: Exploring reimbursement and healthcare systems across the Middle East
Rita Shorjian, Market Access Head - Near East And North West Africa, AbbVie
Roundtable 13: Access and HTA considerations for Russia and CIS countries
Nabil Seidov, Deputy Head Of Department For Health Policy And Planning Of Public Health And Reforms Centre, Ministry of Healthcare of Azerbaijan Republic
Irina Kurashkina, Advisor, External Affairs Department, S.T.A.D.A.
Anastasiya Stepanova, State Authorities Manager, JSC Nizhpharm
Nuriya Musina, Head Of Development, Federal State Budgetary Institution, The Center For Healthcare Quality Assessme, Ministry of Health Russian Federation
Roundtable 14: Indication based pricing- where are we?
Nicki Catterick, Senior Director, Global Market Access And Pricing, Merck Group
Roundtable 15: Access and HTA considerations for Turkey, Kazakhstan and Ukraine
Oresta Piniazhko, Director, Hta Department, Ministry of Health of Ukraine
Kamilla Gaitova, Head Of Center For Health Economics And Health Technology Assessment, Republican Center for Health Development, Kazakhstan
Kagan Atikeler, Pharmacist, Turkish Medicines and Medical Devices Agency
Roundtable 16: Exploring the value from repurposing drugs: Who Benefits?
Douglas Foerster, Head Market Access Europe And Row, Santhera
Roundtable 17: Working together with NGOs, Advocates, Pharma & Government to improve outcomes for families?
Edmund Lim, Co-Founder, We CARE Journey
Roundtable 18: Exploring challenges and opportunities across Africa on achieving new affordable strategies for Universal Health Coverage
Sagie Pillay, Chief Operating Officer, Wits Health Consortium
Roundtable 19: Exploring innovative reimbursement and payment models for orphan drugs
Sebastian Soluch, Head Of Market Access And Pricing, Europe, Stemline Therapeutics Inc
Roundtable 1: Efficacy to Effectiveness - E2E – translating the promise of clinical trials to the real world
Chris Pashos, Vice President Of Global Evidence Strategy, AbbVie
Roundtable 20: Branded combo-pricing: Where to next?
Yves Samel, Market Access Strategy Leader And Global Pricing Manager, Bayer
Roundtable 21: Exploring Patient Access in Belgium: challenges and opportunities
Katrien Van Geyt, Head Of Market Access, Belgium And Luxembourg, Takeda
Roundtable 22: Achieving greater collaboration with HTAs: Insights from EUnetHTA & Industry
Marcus Gaurdian, Chief Operating Officer, EUnetHTA
Roundtable 23: Exploring orphan drugs in emerging markets
Lisette Kaskens, Senior Global Market Access Manager, Advanced Accelerator Applications
Roundtable 24: Developments in pricing and patient access for speciality treatments
Keith White, Vice President And Head, Global Market Access, Corbus Pharmaceuticals
Jenny Ebert, National Account Director, Genzyme Sanofi Corp
Roundtable 25: Reserved for Syneos Health
Roundtable 26: Reserved for Life Science Dynamics
Roundtable 27: Exploring reimbursement models: Working with external stakeholders to improve outcomes
Gomathi Kaliappan, Global Market Access (Health Systems Strategy, Value Recognition), Roche
Roundtable 28: Oncology drug market: a high-growth, high-price therapeutic area
Elena Lungu, Manager Of Policy Development, Government of Canada (Canada)
Roundtable 29: Game-changing policies for game-changing innovations: what regulatory changes to ensure the development, diffusion and sustainability of new technologies
Julien Patris, Associate Director Of Market Access And Policy For Europe And Canada, Alnylam
Roundtable 2: How do you include the patient perspective in a outcomes-based contract?
Jolanda Koenders, Head Of Market Access Netherlands, Takeda
Roundtable 30: Pricing Competition from Launch to Loss of Exclusivity
Adam Plich, Managing Director, Plich Advisory
Roundtable 31: HTA developments across Eastern Europe
Tatyana Benisheva, Professor In Drug Regulatory Affairs, Bulgarian Association For Drug Information
Roundtable 32: Exploring access and pricing challenges for low to middle income countries
Giovanny Leon, Pricing And Market Access Director For Latin America And Canada, Novartis AG
Marijn Verhoef, Engagement Manager, Access to Medicine Foundation
Roundtable 33: Access and pricing considerations for CAR-T development
Nuno Prego Ramos, Chief Executive Officer, CellmAbs
Roundtable 34: Exploring Free of Charge supply model for an orphan drug at public healthcare coverage in Argentina
Marcelo Sal, Head Of Market Access And Pricing, Argentina, PTC Therapeutics
Roundtable 35: Value-based contracting in the world oncology
Roundtable 3: Capability building for RWE
Angelina Irizari Policarpio, Head Of Heor And Real World Evidence Communications, Eisai
Elena Panitti, Global Rwe Capability Building Lead, Novartis
Roundtable 4: Payer insights and engagement for BeneLux
Diane Kleinermans, Advisor To The Ministry Of Health And Social Affairs, Belgian Federal Government
Bart Vermeulen, Deputy Director Healthcare At Office Of The Minister Of Social Affairs And Public Health, Belgian Federal Government
Francis Arickx, Head Of The Directorate Reimbursement Of Medicines And Pharmaceutical Policy, National Institute for Health and Disability Insurance RIZIV-INAMI
Roundtable 5: HTA insights and engagement for Italy
Marco Marchetti, Director Of The National Center For Health Technology Assessment, Istituto Superiore di Sanita
Roundtable 6: A tale of two diseases: how orphan drugs can navigate NICE
Lindsay Weaver, Chief Executive Officer, Metabolic Support UK
Roundtable 7: Achieving positive reimbursement negotiations
Hassan Bruneo, Associate Director, Alnylam Switzerland Gmbh
Roundtable 8: The development of a patient advocate – How to find experienced and qualified patient advocates- The Continual Professional Development approach
Nadia Bodkin, Rare Disease Advocacy Professional, Rare Advocacy Movement
Roundtable 9: Using Health Economic Studies to Support Access and Value
Fabrizio Gianfrate, Professor Of Health Economics, Market Access Advisor, Universities of Rome and Ferrara
Mar 1814:10
Conference pass

Chair’s remarks

EVIDENCE
Chris Pashos, Vice President Of Global Evidence Strategy, AbbVie
Mar 1814:10
Conference pass

Chair’s remarks

PRICING & MARKET ACCESS
Gustavo Saraiva Dos Anjos, Global Market Access Director For Biologics, GlaxoSmithKline
Mar 1814:10
Conference pass

Chair’s remarks

RARE DISEASES
John P Hakanson, Global Head Of Strategic Pricing, CSL Behring
Mar 1814:10
Conference pass

Chair’s remarks

BIG DATA, DIGITAL HEALTH & ANALYTICS
Francis Crawley, Executive Director, Strategic Initiative For Developing Capacity In Ethical Review (Sidcer), Good Clinical Practice Alliance (GCPA)
Mar 1814:10
Conference pass

Chair’s remarks

HTA
Reg Waldeck, Market Access Strategy Leader, Bayer Corp
Mar 1814:10
Conference pass

Chair’s remarks

THE FAR EAST
Navin Joshi, Global Head Of Pricing, Classic And Established Products. Global Pharma, Head Of Pricing and Access Capabilities, Emerging Marke, GlaxoSmithKline
Mar 1814:15
Conference pass

Can Pharma save $1 billion through the strategic use of RWE?

EVIDENCE
Melvin Olson, Global Head Rwd Strategy And Innovation, Novartis Pharma
Mar 1814:15
Conference pass

New and improved outcomes-based contracting: new implementation

PRICING & MARKET ACCESS
Jolanda Koenders, Head Of Market Access Netherlands, Takeda
Mar 1814:15
Conference pass

Registries and reimbursement for orphan drugs in Germany

RARE DISEASES
Friedhelm Leverkus, Director Health Technology Assessment And Outcomes Research, Pfizer
Mar 1814:15
Conference pass

From Digital To Big Data Analytics & AI In Real World Data

BIG DATA, DIGITAL HEALTH & ANALYTICS
Igor Rudychev, Head Of Us Digital, Data, And Innovations, AstraZeneca
Mar 1814:15
Conference pass

Horizon scanning in the HTA process; helping to facilitate UK market access

HTA
Stephen Hall, Knowledge Exchange Associate, NIHR Innovation Observatory, Newcastle University
Mar 1814:15
Conference pass

HTA insights for South Korea

THE FAR EAST
Jeonghoon Ahn, Director, National Evidence-based Healthcare Collaborating Agency
Mar 1814:15
Conference pass

Latest developments in value frameworks

VALUE
Gwilym Thompson, Director Worldwide Heor, BMS
Mar 1814:55
Conference pass

Effective RWE strategy for regulatory approval and reimbursement

EVIDENCE
Nneka Onwudiwe, Founder And Chief Executive Officer, Pharmaceutical Economics Consultants of America (PECA) LLC
Mar 1814:55
Conference pass

Value-based Contracting Status and Outlook

PRICING & MARKET ACCESS
Birgit Holz, Global Head Of Contracting Innovation, Sanofi
Mar 1814:55
Conference pass

The continuing changing landscape in creating value beyond price for rare disease products in the US

RARE DISEASES
Diann Potestio, Vice President Market Access, Ascendis Pharma
Mar 1814:55
Conference pass

Diabetes care in the world of digital health: What does the evidence say?

BIG DATA, DIGITAL HEALTH & ANALYTICS
Mar 1814:55
Conference pass

Pricing and reimbursement in Russia

HTA
Vitaly Omelyanovskiy, General Director, Center Of Healthcare Quality Assessment And Control, Federal State Budgetary Institution, the Center for Healthcare Quality Assessment and Control of the Ministry of Health of the Russian Federation
Mar 1814:55
Conference pass

Market access conditions and healthcare for the Far East and Australasia

THE FAR EAST
Diane Munch, Vice President, Global Pricing, Patient and Health Impact, Pfizer
Mar 1814:55
Conference pass

Understanding the patient’s perspective when assessing value

VALUE
Daniel Jackson, Global Head Of Market Access, Solutions And Strategy, UCB
Mar 1815:15
Conference pass

Chair’s remarks

EMERGING MARKETS
Kevin Loth, Vice President, Corporate Affairs And Policy, Worldwide Markets, Celgene
Mar 1815:15
Conference pass

Chair’s remarks

EVIDENCE
Angelina Irizari Policarpio, Head Of Heor And Real World Evidence Communications, Eisai
Mar 1815:15
Conference pass
Mar 1815:15
Conference pass

Chair’s remarks

BIG DATA, DIGITAL HEALTH & ANALYTICS
Sandro Cesaro-Tadic, Head Pricing I8 & Product Pricing Strategies, Roche
Mar 1815:15
Conference pass

Chair’s remarks

HTA
Kevin Rieger, Head Of Eu Affairs, BPI
Mar 1815:15
Conference pass

Chair’s remarks

VALUE
Gavin Lewis, Intenational Access Lead, Amgen
Mar 1815:20
Conference pass

Challenges for reimbursement and innovation in Latin America

EMERGING MARKETS
Giovanny Leon, Pricing And Market Access Director For Latin America And Canada, Novartis AG
Mar 1815:20
Conference pass

Living with and Beyond Cancer: The Missing Evidence

EVIDENCE
Richard Stephens, Patient Advocate, Independant
Mar 1815:20
Conference pass

Market access for gene therapies in Germany

PRICING & MARKET ACCESS
Axel Boehnke, Director Market Access Eu North, PTC Therapeutics
Mar 1815:20
Conference pass

Developing advanced therapies for rare diseases: is this sustainable?

RARE DISEASES
Diego Ardigo, R&D Rare Diseases Unit Head, Chiesi Farmaceutici SpA
Mar 1815:20
Conference pass

Big data & AI in pricing and access to medicines

BIG DATA, DIGITAL HEALTH & ANALYTICS
Francis Crawley, Executive Director, Strategic Initiative For Developing Capacity In Ethical Review (Sidcer), Good Clinical Practice Alliance (GCPA)
Mar 1815:20
Conference pass
Mar 1815:20
Conference pass

How we deliver value with the patient in mind

VALUE
Peter Mulley, Director Global Market Access, ViiV Healthcare
Mar 1815:40
Conference pass

Access and pricing considerations in the world of innovative diagnostics

BIG DATA, DIGITAL HEALTH & ANALYTICS
Laura O'Hanlon, Director Of International Market Access, Policy and Advocacy, Myriad genetics
Mar 1815:40
Conference pass

Working with AIFA to establish the value of new drug therapies

HTA
Arrigo Paciello, Scientific Advisor, AIFA
Mar 1816:00
Conference pass

The link between HTA and decision-making in resource allocation

EMERGING MARKETS
Andres Pichon Riviere, Executive Director And Director Of Health Technology Assessment And Economic Evaluations, I.E.C.S.
Mar 1816:00
Conference pass

The use of Big Data and what Pharma can learn

EVIDENCE
Enkeleida Nikai, Head Of Real World Evidence, Senior Director At Janssen Europe, Middle East And Africa (Emea), Janssen Pharmaceutical
Mar 1816:00
Conference pass

Access, Pricing and Value in the world of oncology and combination therapies

PRICING & MARKET ACCESS
Patrick Mollon, Heor Consultant, Gmap, Ipsen Pharma
Mar 1816:00
Conference pass

Management and sustainability of Orphan Drugs in the US

RARE DISEASES
Saira Jan, Director, Enterprise Pharmacy, Blue Cross Blue Shield of New Jersey
Mar 1816:00
Conference pass

How transparency in R&D can improve access conditions?

BIG DATA, DIGITAL HEALTH & ANALYTICS
Jaume Vidal, Policy Advisor, Eu Projects, Health Action International
Mar 1816:00
Conference pass

The DIVE framework: how to incorporate all information into your estimation process: Direct evidence, Indirect evidence, validation and external information incorporation?

HTA
Mario Ouwens, Senior Statistical Science Director, Astra Zeneca
Mar 1816:00
Conference pass

How do traditional drugs deliver value in the world of gene therapies

VALUE
Juan Roman, Head Of Market Access And Pricing, Acceleron Pharmaceuticals, Inc.
Mar 1816:50
Conference pass

Chair’s remarks

PAYER ENGAGEMENT & STRATEGY
Kart Veliste, Chief Specialist At Department Of Medicines And Medical Devices, Haigekassa Estonia
Mar 1816:50
Conference pass

Chair’s remarks

EMERGING MARKETS
Martin Price, Vice President Of Health Economics, Market Access And Reimbursement, Johnson & Johnson
Mar 1816:50
Conference pass

Chair’s remarks

GOVERNMENTAL AFFAIRS
Gundula Schneidewind, Head Ethics And Compliance, Europe And Canada, Takeda
Mar 1816:50
Conference pass

Chair’s remarks

EVIDENCE
Anjan Chatterjee, Global Head Of Real World Evidence, Boehringer Ingelheim Pharma GmbH & Co. KG
Mar 1816:50
Conference pass

Chair’s remarks

PRICING & MARKET ACCESS
Cristina Martin-Rinconada, Head Of Value And Access For International Partners Markets (Mena And Ceer Regions), Biogen
Mar 1816:50
Conference pass

Chair’s remarks

BIG DATA, DIGITAL HEALTH & ANALYTICS
Vitaly Doban, Executive Director, Head Of Applied And Advanced Analytics (Rwe, Medical), Novartis
Mar 1816:55
Conference pass

Market access and pricing conditions across the Middle East and Africa

EMERGING MARKETS
Ayman Semaan, Head Of Market Access, Algorithm
Mar 1816:55
Conference pass

Should a large payer like AXA transform its role from prevention and care coordination to healthcare delivery

PAYER ENGAGEMENT & STRATEGY
Charles De Cidrac, Director Of Health Insurance, AXA
Mar 1816:55
Conference pass

What is the government’s role in US pricing decisions?

GOVERNMENTAL AFFAIRS
Robert Popovian, Vice President Of Government Relations, Pfizer
Mar 1816:55
Conference pass

Evidence requirements for HTAs across Europe

EVIDENCE
Giovanni Tafuri, Eunethta, Senior Scientific Officer, National Health Care Institute (ZIN), the Netherlands
Mar 1816:55
Conference pass

The Swedish market: Supporting regional payers in managed introduction and prioritisation of new drug therapies

PRICING & MARKET ACCESS
Mar 1816:55
Conference pass

The patient’s journey for neurological diseases

RARE DISEASES
Lara Pippo, Head Of Market Access, CSL Behring
Mar 1816:55
Conference pass

Digital Medicines: Where are we now and what next

BIG DATA, DIGITAL HEALTH & ANALYTICS
Oliver Gassner, Head G4A Digital Health Intelligence Emea, Bayer
Mar 1817:15
Conference pass

Pharmaceutical Pricing Policy and Access in South Africa, A Funder’s Perspective – Key Focus on Rare Diseases

EMERGING MARKETS
Inez Naidu, Head - Discovery Health Medicines Unit, Discovery Health
Mar 1817:15
Conference pass

Working with the government in Brazil to encourage innovation in access and the impact across Latin America

GOVERNMENTAL AFFAIRS
Marcela Junqueira, Head Of Strategic Affairs And Health Economics, Janssen Pharmaceutical
Mar 1817:15
Conference pass

Patient engagement in preparation for HTA submissions and acceptance of data

EVIDENCE
Stefan Holmstrom, Head, Hta Strategy And Pro Excellence, Astellas Pharma
Mar 1817:15
Conference pass

Patient engagement within the HTA process for orphan drugs

RARE DISEASES
Stefan Holmstrom, Head, Hta Strategy And Pro Excellence, Astellas Pharma
Mar 1817:15
Conference pass

Exploring the world of digital healthcare and how we can improve outcomes in market access and evidence

BIG DATA, DIGITAL HEALTH & ANALYTICS
Hans Hofstraat, Vice President, Philips Research
Mar 1817:35
Conference pass

How the political climate is changing the necessity for fairer pricing

GOVERNMENTAL AFFAIRS
Ad Schuurman, Senior Advisor International Affairs, National Health Care Institute (ZIN), the Netherlands
Mar 1817:35
Conference pass

Payer engagement in Italy and across Europe

PAYER ENGAGEMENT & STRATEGY
Andrea Mantovani, Former Head Of Value, Access And Policy For Biopharma Companies, Independent
Mar 1817:35
Conference pass

The Sanofi Espoir Foundation- improving access in Africa

EMERGING MARKETS
Valerie Faillat, Head Of Sanofi Espoir Foundation, Sanofi
Mar 1817:35
Conference pass

Looking at the evidence after launch: addressing access hurdles across different markets

EVIDENCE
Rasmus Jensen, Global Head Of Market Access, Camurus
Mar 1817:35
Conference pass

Market access developments for Russia

PRICING & MARKET ACCESS
Daria Tolkacheva, Head Of Health Economics, JSC BIOCAD
Valentin Dodonov, Deputy General Head Of Market Access, BIOCAD
Mar 1817:35
Conference pass

The Hercules Project: Patient-led Access in Rare Diseases

RARE DISEASES
Josie Godfrey, Director, JG Zebra Consulting
Mar 1817:35
Conference pass

Commercial initiatives within the digital space

BIG DATA, DIGITAL HEALTH & ANALYTICS
Ali Ciger, Commercial Director, Pain, Pfizer

Create your personal agenda –check the favourite icon

Mar 1908:55
Conference pass

Chair’s opening remarks

Keynotes
Sarah Pitluck, Head, Global Pricing And Reimbursement, Spark Therapeutics
Mar 1909:00
Conference pass

Market Access considerations from NICE

Keynotes
Carla Deakin, Programme Director - Commercial And Managed Access, NICE
Mar 1909:40
Conference pass

Achieving greater stakeholder engagement and innovation to improve outcomes

Keynotes
  • What are the key initiatives in Europe and across the world aimed at improving cooperation?
  • How is innovation in access, pricing or evidence helping to improve outcomes?
  • How can we work better together with key stakeholders to improve health care efficiency?
Sarah Pitluck, Head, Global Pricing And Reimbursement, Spark Therapeutics
Ulf Staginnus, Senior Vice President, Head Of Global Market Access And Pricing, Ipsen Pharma
Rajakanth Raman, Executive Director, Rainbow Across Borders Limited
Ulrike Jacobi, Head Of External Affairs And Market Access, AMGEN
Gustavo Saraiva Dos Anjos, Global Market Access Director For Biologics, GlaxoSmithKline
Tamir Singer, Head Of Commercial Development, Specialised Commissioning, NHS England
Evert Jan Van Lente, Director Of Eu Affairs, AOK Bundesverdand
Mar 1911:00
Conference pass

Roundtables

Keynotes
Roundtable 10: How to establish a market access department from scratch?
Michael Müller, Head Of Market Access, Western Europe, SUN Pharma
Roundtable 11: Evidence solutions and CAR-T
Clare Hague, Therapy Area Market Access Lead, Hematology, Janssen Pharmaceutical
Roundtable 12: Exploring the international reference pricing landscape
Tanya Aiden, Global Products Lead, BIOCAD
Roundtable 13: Patient Assistance Programs and Access Structure in the US
Kankendria Ingram, Independent, Independent
Roundtable 14: Achieving better alignment amongst stakeholders regarding definitions and concepts of value in diagnostics
Benjamin Gannon, Vice President International Access, Policy And Advocacy, Myriad genetics
Roundtable 15: Market access, Pricing, Payer & HTA developments for the Nordic Region
Sune Lindgaard, Chief Of Business Intelligence, Amgros, Denmark
Steinar Madsen, Medical Director, Norwegian Medicines Agency, Norway
Einar Andreassen, Senior Adviser, Hta And Reimbursement, Norwegian Medicines Agency
Dorthe Bartels, Strategic Adviser, Amgros
Roundtable 16: Real world data and its utility in HTA decisions
Madhusudan Kabra, Director, Evidence Generation, Otsuka Pharmaceutical
Roundtable 17: Patient based generated evidence
David Elvira, Heads Eu Public Affairs, Sanofi
Roundtable 18: Market Access and pricing considerations for Spain
Carme Pinyol, Head Of Pricing And Market Access Southern Europe, Pierre Fabre
Igor Beitia Ortiz De Zárate, Director Market Access Southern Europe Region, PTC Therapeutics
Jaime Espin, Professor, Andalusian School Of Public Health
Jonathan Galduf, Market Access Manager, Sun Pharmaceutical Industries Limited
Roundtable 19: Importance and requirements of registry data in HTA processes for orphan drugs across Europe
Ulrike Beckert, Senior Patient Access Manager Dach, Sobi - Swedish Orphan Biovitrum AB (publ)
Roundtable 20: Exploring innovative reimbursement models for Advanced Therapy Medicinal Products
Carlo Incerti, Operating Partner, Forbion
Roundtable 21: Market access considerations for oncology therapeutics
Adam Nosal, Head Of Market Access, Oncology Europe, AstraZeneca
Roundtable 22: Exploring High Cost Novelty Medicine Access and HTA in South Africa
Niri Bhimsan, Head - Health Technology Assessment, Discovery Health
Inez Naidu, Head - Discovery Health Medicines Unit, Discovery Health
Roundtable 23: Exploring the long-term sustainability in the world of biosimilars
Diogo Piedade, Health Economics Advisor, Medicines for Europe
Roundtable 24: The evolving perspective of price transparency
Matt Slabbert, Head Of Market Access, Advocacy And Policy, Anz, Bayer Pharmaceuticals
Roundtable 25: Exploring HTA requirements and novel payment methods for anti-biotics
Warren Cowell, Market Access Director, Shionogi Inc
Roundtable 26: Achieving the best outcomes when negotiating managed entry agreements
Inneke Van De Vijver, Strategic Advisor – Reimbursement Pharmaceuticals, N.I.H.D.I.
Roundtable 27: Reserved for Lifescience Dynamics
Roundtable 28: Reserved for Syneos Health
Roundtable 29: Exploring repurposed products for rare diseases
Amer Omar, Senior Director, Lupin
Roundtable 30: Industry and patients working together for better access
Mary Lynne Van Poelgeest-Pomfret, President, President of the World Federation for Incontinence and Pelvic Pain - WFIP
Roundtable 5: Exploring the evolution of the value framework to assess drugs in Italy
Americo Cicchetti, Director, Universita Cattolica Del Sacro Cuore
Roundtable 6: Advanced Therapies: The role of registries in convincing payers about long-term effects
Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (Belgium)
Roundtable 7: Exploring Biosimilars in the USA and Europe – latest developments
Sue Naeyaert, Vice President Global Government Affairs, Policy And Pharmacoeconomics Biosimilars, Fresenius Kabi
Robert Orzechowski, Chief Operating Officer, Lancaster Cancer Centre
Roundtable 8: Accelerating Access to treatments for Rare Diseases
Gina Ewy, Head Of Global Market Access, Hansa Biopharma
Rob De With, Head Of Rare Diseases Of Europe And Canada, Takeda
Roundtable 9: How to involve patients in drug research and market access?
Dorinda Silva, Volunteer Patient Advocate, Portuguese Association for CDG and other Rare Metabolic Diseases
Roundtables 1: Innovation in Contracting
Diar Fattah, Global Director, Innovative Value Strategies and Evidence (Respiratory), AstraZeneca
Fabrizio Zucca, Director Market Access Dach, Intercept Pharmaceuticals Inc
Birgit Holz, Global Head Of Contracting Innovation, Sanofi
Roundtables 2: Achieving greater collaboration amongst payers, HTAs, pharma and patients to improve outcomes
Irina Odnoletkova, Vice President Health Technology Assessment, Apogenix Gmbh
Jost Leemhuis, Head Of Safety Science, Roche
Roundtables 3: Exploring innovative payment and evidence development models for rare diseases
Simon Shohet, Senior Director, Global Market Access And Pricing, Ipsen
Roundtables 4: How to improve the environment for value-added medicines in Europe
Catarina Lopes Pereira, Market Access, Senior Manager and Coordinator Of The Value Added Medicines Sector Group, Medicines for Europe
Mar 1912:00
Conference pass

Chair’s remarks

AFFORDABILITY
Christina Vandoros, Director, Macroeconomics And Health Policy - Emea, Janssen
Mar 1912:00
Conference pass

Chair’s remarks

ADVANCED THERAPIES
Omar Dabbous, Vice President, Health Economics And Outcomes Research, AveXis
Mar 1912:00
Conference pass

Chair’s remarks

MANAGED ENTRY AGREEMENTS
Giuseppe Rosano, Member Of The Cardiovascular Working Party, European Medicines Agency
Mar 1912:00
Conference pass
Mar 1912:00
Conference pass

Chair’s remarks

PRICING & MARKET ACCESS
David Watson, Director Pricing And Reimbursement, ABPI
Mar 1912:00
Conference pass

Chair’s remarks

RARE DISEASES
Ines Alves, President, ANDO Portugal
Mar 1912:05
Conference pass

Experiences from managed entry agreements

MANAGED ENTRY AGREEMENTS
Bart Van Den Daele, Head of External Affairs – Director Market Access, Gilead Sciences
Mar 1912:05
Conference pass

Political factors when considering affordability

AFFORDABILITY
Mar 1912:05
Conference pass

Federated & Harmonised Real World Evidence in the EU 2020+: A Convergence of Intent, Collaboration & Technology?

EVIDENCE
Mar 1912:05
Conference pass

Governance in the world of access and pricing

PRICING & MARKET ACCESS
Claudia Neuber, Head Of Global Pricing Implementation, AstraZeneca
Mar 1912:05
Conference pass

Innovation in treating rare diseases: HTA approach in Scotland

RARE DISEASES
Mark Macgregor, Medical Director, Golden Jubilee National Hospital
Mar 1912:05
Conference pass

Risk sharing agreements for cell and gene therapies

HTA
Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (Belgium)
Mar 1912:25
Conference pass

Immediate Access to treatment for Rare Disease patients

RARE DISEASES
Rob De With, Head Of Rare Diseases Of Europe And Canada, Takeda
Mar 1912:45
Conference pass

Pricing for a Cell therapy Portfolio

ADVANCED THERAPIES
Inge Bliestle, Chief Operating Officer, TolerogenixX
Mar 1912:45
Conference pass

Solving the Affordability Challenge – what pharma companies can do beyond philanthropy

AFFORDABILITY
John Alter, Vice President Pricing And Market Access, Pfizer
Mar 1912:45
Conference pass

What to watch out for in implementing managing entry agreements

MANAGED ENTRY AGREEMENTS
Shanthy Krishnaraja, Senior Director, Market Access And Strategy, Seqirus
Mar 1912:45
Conference pass

Use of reimbursement data for research with respect to GDPR

EVIDENCE
Gottfried Endel, Ebm, Hta Team Leader, H.V.B.
Mar 1912:45
Conference pass

US insights: Alternative payment methodologies

PRICING & MARKET ACCESS
Ed Pezalla, Former Vice President, National Medical Director For Pharmaceutical Policy And Strategy, Aetna; a CVS Pharmacy Health Company
Mar 1912:45
Conference pass

Innovative payment and evidence development models for rare diseases

RARE DISEASES
Simon Shohet, Senior Director, Global Market Access And Pricing, Ipsen
Mar 1914:05
Conference pass

Chair’s remarks

BIOSIMILARS
Steinar Madsen, Medical Director, Norwegian Medicines Agency, Norway
Mar 1914:05
Conference pass

Chair’s remarks

ADVANCED THERAPIES
Adam Heathfield, Senior Director Of Global Health And Value Innovation Centre, Pfizer Ltd
Mar 1914:05
Conference pass

Chair’s remarks

MANAGED ENTRY AGREEMENTS
Rudy Dupree, Senior Project Manager, Eunethta Wp4, EUnetHTA
Mar 1914:05
Conference pass

Chair’s remarks

EVIDENCE
Ramon Hernandez Vecino, Head Of Real World Evidence Data and Analytics Engagement Lead RandD, Sanofi
Mar 1914:05
Conference pass

Chair’s remarks

PRICING & MARKET ACCESS
Anne Marciniak, Head Of Market Access, Europe, Aimmune
Mar 1914:05
Conference pass

Chair’s remarks

RARE DISEASES
Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (Belgium)
Mar 1914:10
Conference pass

Achieving Sustainability in Biosimilars

BIOSIMILARS
Steinar Madsen, Medical Director, Norwegian Medicines Agency, Norway
Mar 1914:10
Conference pass

Experiences from a payer point of view: insights from Denmark

MANAGED ENTRY AGREEMENTS
Sune Lindgaard, Chief Of Business Intelligence, Amgros, Denmark
Mar 1914:10
Conference pass

How to evaluate and value gene therapies

ADVANCED THERAPIES
Omar Dabbous, Vice President, Health Economics And Outcomes Research, AveXis
Mar 1914:10
Conference pass

Capability-building for SMEs: Starting from Scratch

EVIDENCE
Alexander Bastian, Vice President Of Value And Market Access, Galapagos
Mar 1914:10
Conference pass

Developments in German legal framework for drug assessment, reimbursement and supply

PRICING & MARKET ACCESS
Marco Penske, Head Of Market Access And Health Care Affairs, Boehringer-Ingelheim
Mar 1914:10
Conference pass

The incentives’ review by the EU Commission and its implication on OMPs

RARE DISEASES
Ana Palma, Senior Director Global Hta And Patient Access Lead, Sobi
Mar 1914:30
Conference pass

Perspectives from the Alliance for Regenerative Medicine: improving access to cell and gene therapies

ADVANCED THERAPIES
Paolo Morgese, Director, Market Access And Member Relations, Alliance for Regenerative Medicine
Mar 1914:30
Conference pass

The long-term sustainability of Biosimilars

BIOSIMILARS
Olga Diachenko, Market Access Manager Europe, Accord Healthcare
Mar 1914:30
Conference pass

Topic tbc

MANAGED ENTRY AGREEMENTS
Entela Xoxi, Former Aifa, Universita Cattolica Del Sacro Cuore
Mar 1914:30
Conference pass

Redefining the Orphan Drug Act in the US to reach a wider population

RARE DISEASES
Bradley Burnam, Chief Executive Officer, Turn Therapeutics
Mar 1914:50
Conference pass

A look at legislation for Biosimilars in Germany

BIOSIMILARS
Michael Ermisch, Specialist, Department Of Pharmaceuticals, G.K.V. Spitzenverband
Mar 1914:50
Conference pass

Looking at Value for Advanced Therapies in Quebec

ADVANCED THERAPIES
Luc Boileau, Chairman And Chief Executive Officer, INESSS
Mar 1914:50
Conference pass

The patient perspective in managed entry agreements

MANAGED ENTRY AGREEMENTS
Rob Burley, Director Of Campaigns, Care And Support, The Muscular Dystrophy U.K.
Mar 1914:50
Conference pass

Capability-building in the development of orphan drugs

EVIDENCE
Martine Zimmermann, Global Head Of Regulatory Affairs, Alexion Pharmaceuticals
Mar 1914:50
Conference pass

Market access for Germany with single arm studies

PRICING & MARKET ACCESS
Jorg Tomeczkowski, Head Of Market Access, Janssen Cilag Germany
Mar 1914:50
Conference pass

Where do we go from here - bridging the gap from regulatory approval to market access using MoCA

RARE DISEASES
Anna Bucsics, Project Advisor, MoCA - Mechanism of Coordinated Access to Orphan M
Mar 1915:40
Conference pass

Chair’s remarks

CONTRACTING AND PRICE TENDERING
Mauricio Alvarez Reyes, Independent, Independent
Mar 1915:40
Conference pass

Chair’s remarks

ADVANCED THERAPIES
Steven Flostrand, Senior Director Of Pricing And Market Access, Celgene
Mar 1915:40
Conference pass

Chair’s remarks

PATIENT ADOVACY
Dawn Torrence Ireland, President And Founder, C.H.E.R.U.B.S.
Mar 1915:40
Conference pass

Chair’s remarks

EVIDENCE
Wim Goettsch, Special Hta-Advisor, Zorginstituut
Mar 1915:40
Conference pass

Chair’s remarks

PRICING & MARKET ACCESS
Hanadi Nahas, Chairman And General Manager, Access Core
Mar 1915:40
Conference pass

Chair’s remarks

RARE DISEASES
Sheela Upadhyaya, Associate Director Hst, National Institute for Health and Care Excellence
Mar 1915:45
Conference pass

Innovative Value based contracting for gene therapies

CONTRACTING AND PRICE TENDERING
Kevin Mayo, Global Head Of Market Access And New Products, PTC Therapeutics
Mar 1915:45
Conference pass

Reimbursement for gene therapies

ADVANCED THERAPIES
Stefan Vegter, Market Access Manager, Novartis
Mar 1915:45
Conference pass

The importance of patient advocacy for Market Access

PATIENT ADOVACY
Steve Sandor, Vice President, Market Access And Trade, Paratek Pharmaceuticals , Inc.
Mar 1915:45
Conference pass

Real-world evidence and the 2020 NICE Methods Update

EVIDENCE
Micah Rose, Senior Scientific Adviser, Health Economic Modelling, National Institute for Health and Care Excellence
Mar 1915:45
Conference pass

Patient acceptability of self-injectables

PRICING & MARKET ACCESS
Marie-Liesse Le Corfec, Global Portfolio Marketing Head, Ps, B.D. Pharmaceuticals Systems
Mar 1915:45
Conference pass

Working with stakeholders to improve access to rare disease treatments

RARE DISEASES
Natasa Zibelnik, Global Head Of Market Access, E.U.S.A. Pharma
Mar 1916:05
Conference pass

Developments in CAR-T and latest regulatory requirements

ADVANCED THERAPIES
Detlev Parow, Head Pharmaceutical Department, D.A.K.
Mar 1916:05
Conference pass

Latest developments on indication-based pricing

CONTRACTING AND PRICE TENDERING
Bertrand Tardivel, General Manager, Frehel GmbH
Mar 1916:05
Conference pass

Patient financial toxicity: challenges and options

PATIENT ADOVACY
Robert Orzechowski, Chief Operating Officer, Lancaster Cancer Centre
Mar 1916:05
Conference pass

Topic tbc

EVIDENCE
Deven Chauhan, Senior Director, Value Evidence Leader, GlaxoSmithKline
Mar 1916:05
Conference pass

Latest developments in biomarkers

PRICING & MARKET ACCESS
Irina Odnoletkova, Vice President Health Technology Assessment, Apogenix Gmbh
Mar 1916:05
Conference pass

Bridging the Gap between Payers, Patients & the Advocates Navigating Access to Care

RARE DISEASES
Elizabeth Johnson, Biologics Coordinator, Allergy Partners, P.A.
Mar 1916:25
Conference pass

Innovative contracting and payment models for cell and gene therapies

CONTRACTING AND PRICE TENDERING
Ramesh Arjunji, Senior Director Heor And Rwe, AveXis
Mar 1916:25
Conference pass

The determinacy of HTA for ATMPs in Europe

ADVANCED THERAPIES
Renske Ten Ham, Researcher, Utrecht University
Mar 1916:25
Conference pass

The value provided to pharma through patient advocacy – hard lessons learnt from industry

PATIENT ADOVACY
Nadia Bodkin, Rare Disease Advocacy Professional, Rare Advocacy Movement
Mar 1916:25
Conference pass

The real-world evidence required by Pharma as digital innovation transitions from clinical trials to the adoption within a healthcare setting

EVIDENCE
Vipul Modi, Head Of Transformation For Innovation, Digital And Life Sciences, Oxford Academic Health Science Network
Mar 1916:25
Conference pass

Access challenges for companion diagnostics

PRICING & MARKET ACCESS
Stefan Sladecek, Head Of Market Access Austria, Roche Diagnostics
Mar 1916:25
Conference pass

Using RWE and patient advocacy to ensure patient access in rare disease drug launch

RARE DISEASES
Peter Rutherford, Global Medical Lead Of Orphan Renal Diseases, Vifor Pharma Group
last published: 20/Nov/19 09:55 GMT

Contact us

To sponsor or exhibit:
Edmond Rama
+44 (0)207 092 1052

edmond.rama@terrapinn.com

To speak:
Chris Shanks
+44 (0)207 092 1151

chris.shanks@terrapinn.com